Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve ...
Merck and Japan-based Eisai said on Friday a combination of their therapies failed to extend the lives of patients with a ...
Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...
Discover why Merck presents a compelling long-term investment opportunity with its discounted valuation, robust pipeline, and ...
As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...
The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...
Eli Lilly and Merck & Co. are partnering with Purdue University to launch the Young Institute Pharmaceutical Manufacturing ...
Co., Inc. (NYSE:MRK), a global healthcare leader, faces a complex landscape of opportunities and challenges as it navigates the competitive biopharmaceutical industry. This comprehensive analysis ...
The secretary of Health and Human Services nominee wrote in an ethics agreement that he would keep receiving contingency fees ...
Merck makes a number of vaccines as well as Keytruda, the blockbuster cancer drug. Ms. Canter said ethics guidelines include an impartiality rule that prompts officials to consider the appearance ...
We recently compiled a list of the 15 Stocks to Invest in with Steady Dividends. In this article, we are going to take a look ...
Robert F. Kennedy, Jr. – the vaccine skeptic President Donald Trump has nominated to serve as Health and Human Services ...